Phase Iiib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.

Vifor pharmaKlaus henning jensenNathalie ponnierJaved butlerSwiss stock exchangeVifor pharma groupGlobal head corporate communicationsSwiss exchangeFresenius medical careChief medical officerPrincipal investigatorExecutive committeePharma groupVifor fresenius medical care renal pharmaMedia contactHead corporate communications